High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1535-1538

  Høgdall, Estrid V S ^a,b   Johansen, Julia S ^c   Kjaer, Susanne K ^a   Price, Paul A ^f   Christensen, Lise ^d   Blaakaer, Jan ^e   Bock, Johannes E ^d   Glud, Eva ^a   Høgdall, Claus K ^d  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ovarian cancer; Prognostic factors; Survival; YKL 40

Indexed keywords

CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; OVARY TUMOR; PROGNOSIS; RECURRENT DISEASE; TIME; TUMOR CELL LINE;

ADULT; AGED; CASE-CONTROL STUDIES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECURRENCE; TIME FACTORS;

EID: 1242312462     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1535     Document Type: Article

References (30)

1. Kjær S and Ewertz M: Ovarian Cancer in Denmark 1943-1982: Kræftstatistik nr. 20. Ugeskr Læger 149: 3356-3360, 1987.
2. Qazi F and McGuire WP: The treatment of epithelial ovarian cancer (Review). CA Cancer J Clin 45: 88-101, 1995.
3. Young RC, Walton LA, Ellenberg SS, et al: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322: 1021-1027, 1990. (Pubitemid 20146659)
4. Høgdall CK, Høgdall EVS, Hørding U, Clemmensen I, Nørgaard-Pedersen B and Toftager-Larsen K: Preoperative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 53: 741-746, 1993. (Pubitemid 23350712)
5. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N and Boyes DA: Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65: 264-270, 1985. (Pubitemid 15166989)
6. Mogensen O: Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 44: 207-212, 1992.
7. Høgdall CK: Human tetranectin: methodological and clinical studies. APMIS 86 (Suppl.): 1-31, 1998.
8. Hakala BE, White C and Recklies AD: Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268: 25803-25810, 1993. (Pubitemid 23358198)
9. Shackelton LM, Mann DM and Millis AJ: Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270: 13076-13083, 1995.
10. Morrison BW and Leder P: neu and ras initiate murine mammary tumours that share genetic markers generally absent in c-myc and int-2-initiated tumours. Oncogene 9: 3417-3426, 1994. (Pubitemid 24359377)
11. Renkema GH, Boot RG, Au FL, et al: Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 251: 504-509, 1998. (Pubitemid 28080953)
12. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C and Pastoureau P: YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 285: 926-931, 2001. (Pubitemid 32918025)
13. Malinda KM, Ponce L, Kleinman HK, Shackelton LM and Millis AJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250: 168-173, 1999. (Pubitemid 29391580)
14. Johansen JS, Williamson MK, Rice JS and Price PA: Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7: 501-512, 1992.
15. Rehli M, Krause SW and Andreesen R: Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43: 221-225, 1997. (Pubitemid 27335226)
16. Volck B, Price PA, Johansen JS, et al: YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110: 351-360, 1998. (Pubitemid 28345905)
17. Johansen JS, Cintin C, Jorgensen M, Kamby C and Price PA: Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 31A: 1437-1442, 1995.
18. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S and Nielsen HJ: Serum YKL-40 and colorectal cancer. Br J Cancer 79: 1494-1499, 1999. (Pubitemid 29116810)
19. Høgdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J and Høgdall CK: Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 60: 247-251, 2000.
20. Høgdall EVS, Høgdall CK, Christensen L, et al: Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22: 1859-1864, 2002. (Pubitemid 34839209)
21. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I and Price PA: Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 35: 553-559, 1996.
22. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J and Swindlehurst C: Chondrex: new marker of joint disease. Clin Chem 44: 509-516, 1998. (Pubitemid 28141345)
23. Cox DR: Regression models and life tables. J Roy Stat Soc B 34: 187-220, 1972.
24. Makar AP, Baekelandt M, Trope CG and Kristensen GB: The prognostic significance of residual disease, FIGO substage, tumour histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175-180, 1995.
25. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K, Lorenzen I and Price PA: Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 38: 618-626, 1999. (Pubitemid 29507329)
26. Volck B, Johansen JS, Stoltenberg M, et al: Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 9: 203-214, 2001. (Pubitemid 32390204)
27. Johansen JS, Baslund B, Garbarsch C, Hansen M, Stoltenberg M, Lorenzen I and Price PA: YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 42: 2624-2630, 1999. (Pubitemid 30327181)
28. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O and Price PA: YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 180: 1722-1726, 1999. (Pubitemid 29506483)
29. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C and Bendtsen F: Serum YKL-40 is increased in patients with hepatic fibrosis (In process citation). J Hepatol 32: 911-920, 2000. (Pubitemid 30368084)
30. Tran A, Benzaken S, Saint-Paul MC, et al: Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 12: 989-993, 2000.